Risks Related to Sales, Production, Head Office Operations and Impairment Losses on Securities Due to COVID-19
First written in FY2021. 5 of 9 entries say "Restated". Latest entry: FY2026-H1.
The whole theme swung hardest in 2020: 103 of 175 companies on the "Worse" side.
- FY2026-H1RestatedAnnual report
「During the interim consolidated accounting period, there were no new business or other risks, nor any material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
Explains that there have been no new developments or material changes in risks to sales, production, headquarters operations and other activities arising from COVID-19. - FY2025RestatedAnnual report
「If a major disaster or other event occurs at these operating sites, such as an earthquake, flood, typhoon or other natural disaster, an accident such as a fire, or an infectious disease outbreak, the sites may suffer not only human and property damage but also serious impacts on production and sales activities and headquarters functions, potentially interrupting business operations.」
COVID-19 is reconfirmed not as a standalone item, but as an infectious disease outbreak risk included among major disasters and other events. - FY2024ReframedAnnual report
「If a major disaster or other event occurs at these operating sites, such as an earthquake, flood, typhoon or other natural disaster, an accident such as a fire, or an infectious disease outbreak, the sites may suffer not only human and property damage but also serious impacts on production and sales activities and headquarters functions, potentially interrupting business operations.」
COVID-19 is not presented as a standalone item; the risk of an infectious disease outbreak is incorporated into the risks of major disasters and other events. - FY2024-Q3RestatedAnnual report
「During the nine-month period ended [the current third quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
Explains that there have been no new developments or material changes in risks to sales, production, headquarters operations and other activities arising from COVID-19. - FY2023-Q3RestatedAnnual report
「During the nine-month period ended [the current third quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
Explains that there have been no new developments or material changes in risks to sales, production, headquarters operations and other activities arising from COVID-19. - FY2022The transmission channels for infection-related risks were specifiedAnnual report
「Our Group's business is associated with a broad range of industries. If the pandemic continues for an extended period, restricting business activities and causing customers' corporate activities to stagnate, our performance may be affected by postponed or cancelled orders. In addition, because our production plants are concentrated in a single region, if an outbreak causes a production plant to suspend operations, or if procurement of parts, products and other items is disrupted for an extended period due to disruption of a supply chain that is concentrated primarily in Japan, production of our products may be impeded and our performance may be affected.」
For COVID-19 risks, the Company specified the transmission channels in addition to postponed or cancelled orders, including production plant shutdowns and disruption of a Japan-centered supply chain. - FY2022-Q2RestatedAnnual report
「As measures against COVID-19, the Group has continued since the previous fiscal year to thoroughly disinfect its facilities, take employees' temperatures, stagger working hours, and conduct remote sales using telework, the web and other means. As of the present time, the infection has had no material impact on the Group's performance.」
The Company stated that it was continuing infection-control measures and that COVID-19 had no material impact on business performance at present. - FY2022-Q1MitigatedAnnual report
「As measures against COVID-19, the Group has continued since the previous fiscal year to thoroughly disinfect its facilities, take employees' temperatures, stagger working hours, and conduct remote sales using telework, the web and other means. As of the present time, the infection has had no material impact on the Group's performance.」
The Company stated that it was continuing infection-control measures and that there was no material impact on business performance at present. - FY2021First statedAnnual report
「Our business is associated with a broad range of industries. If the pandemic continues for an extended period, restricting business activities and causing customers' corporate activities to stagnate, our performance may be affected by postponed or cancelled orders. In addition, if a customer becomes insolvent, bad debt losses may arise.」
The Company identified COVID-19 as a standalone risk item for the first time and listed its potential effects on sales, procurement and production, head office functions and securities impairment losses. Although the spread of infection and restrictions on economic activity had already occurred during the fiscal year, each effect was described as a future possibility.